PMID- 17960687
OWN - NLM
STAT- MEDLINE
DCOM- 20071106
LR  - 20071025
IS  - 0032-5481 (Print)
IS  - 0032-5481 (Linking)
VI  - Spec No
DP  - 2006 Apr
TI  - Combination therapy in acute migraine treatment: the rationale behind the current 
      treatment options.
PG  - 20-6
AB  - Combination therapy is used to treat many disorders; for some conditions, it has 
      become first-line treatment or the standard of care. The development and use of 
      novel drug combinations will grow as the understanding of disease pathophysiology 
      and drug pharmacokinetics and pharmacodynamics progresses. In the acute 
      management of migraine, existing drug combinations have proven to be effective, 
      safe, and tolerable. They may offer distinct advantages compared with 
      monotherapy, including both enhanced therapeutic benefits and fewer adverse 
      events (AEs). This article discusses the types of interactions that can occur 
      with combination therapy and their potential effects on efficacy and 
      tolerability. The rationale for using combination therapy will first be discussed 
      within the context of clinical conditions in which it is already the standard of 
      care. This will be followed by a discussion of the rationale for use in migraine.
FAU - Silberstein, Stephen D
AU  - Silberstein SD
FAU - Ruoff, Gary
AU  - Ruoff G
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
RN  - 0 (Analgesics)
RN  - 0 (Antiemetics)
SB  - IM
MH  - Acute Disease
MH  - Analgesics/*therapeutic use
MH  - Antiemetics/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Migraine Disorders/*drug therapy
MH  - Pain Measurement
MH  - Treatment Outcome
RF  - 36
EDAT- 2007/10/26 09:00
MHDA- 2007/11/07 09:00
CRDT- 2007/10/26 09:00
PHST- 2007/10/26 09:00 [pubmed]
PHST- 2007/11/07 09:00 [medline]
PHST- 2007/10/26 09:00 [entrez]
PST - ppublish
SO  - Postgrad Med. 2006 Apr;Spec No:20-6.